{"disease":{"id":"ebv","name":"ebv"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03491605","title":"Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05682703","title":"A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT06681025","title":"Clinical Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Immunocompromised Transplant Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1070,"lead_sponsor_name":"QIAGEN Gaithersburg, Inc","has_results":false},{"nct_id":"NCT05978141","title":"A Registry for People With T-cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT02182986","title":"Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children","phase":"","overall_status":"COMPLETED","enrollment_count":944,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT06908096","title":"Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05778006","title":"Multi-Center Registry for ME/CFS","phase":"","overall_status":"RECRUITING","enrollment_count":650,"lead_sponsor_name":"Technical University of Munich","has_results":false},{"nct_id":"NCT01011712","title":"The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04189835","title":"EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients","phase":"","overall_status":"COMPLETED","enrollment_count":509,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT05604378","title":"Relationship of EBV-positive Gastric Cancer and Multiple Genes Associated With Gastric Carcinogenesis","phase":"","overall_status":"COMPLETED","enrollment_count":460,"lead_sponsor_name":"Saint Vincent's Hospital, Korea","has_results":false},{"nct_id":"NCT03973723","title":"Plasma EBV DNA Monitoring in Post-treatment NPC Patients","phase":"","overall_status":"COMPLETED","enrollment_count":441,"lead_sponsor_name":"Taichung Veterans General Hospital","has_results":false},{"nct_id":"NCT04799275","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","phase":"PHASE2, PHASE3","overall_status":"SUSPENDED","enrollment_count":422,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03314051","title":"Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA","phase":"","overall_status":"COMPLETED","enrollment_count":366,"lead_sponsor_name":"Taichung Veterans General Hospital","has_results":false},{"nct_id":"NCT03984448","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":363,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04058470","title":"Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":140,"lead_sponsor_name":"Huiqiang Huang","has_results":false},{"nct_id":"NCT05011058","title":"An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":102,"lead_sponsor_name":"Viracta Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07536048","title":"A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT03159364","title":"Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Shenzhen Geno-Immune Medical Institute","has_results":false},{"nct_id":"NCT03650231","title":"Comparison of Technics for Determination of Epstein-Barr Virus Serological Diagnosis","phase":"","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT04308278","title":"Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":88,"lead_sponsor_name":"Labo'Life","has_results":false},{"nct_id":"NCT03699904","title":"Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":85,"lead_sponsor_name":"Belfast Health and Social Care Trust","has_results":false},{"nct_id":"NCT04645147","title":"Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":83,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT07488728","title":"Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Beijing Children's Hospital","has_results":false},{"nct_id":"NCT07381738","title":"Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07028047","title":"Evaluation of WGc-043 Injection in Advanced Solid Tumors: Phase I Study","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":64,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04902443","title":"Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04231877","title":"Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT06741072","title":"BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":55,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04181489","title":"Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":55,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT07532746","title":"A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":55,"lead_sponsor_name":"Kousai Bio Co., Ltd.","has_results":false},{"nct_id":"NCT05577364","title":"Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":54,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03038672","title":"Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":54,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04664179","title":"EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT03475212","title":"Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"Pediatric Transplantation & Cellular Therapy Consortium","has_results":false},{"nct_id":"NCT04518982","title":"Sintilimab and Lenalidomide as a Treatment for CAEBV","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":51,"lead_sponsor_name":"Zhao Wang","has_results":false},{"nct_id":"NCT07133763","title":"Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"The Affiliated Hospital of Xuzhou Medical University","has_results":false},{"nct_id":"NCT07029958","title":"Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Beijing Children's Hospital","has_results":false},{"nct_id":"NCT03923842","title":"Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":45,"lead_sponsor_name":"Gruppo Oncologico del Nord-Ovest","has_results":false},{"nct_id":"NCT06834373","title":"Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04705129","title":"Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT07349836","title":"Application of mRNA Immunotherapy Technology in EB Virus Related Diseases","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Xinqiao Hospital of Chongqing","has_results":false},{"nct_id":"NCT04084626","title":"PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT07101536","title":"The Application of mRNA Immunotherapy Technology in Refractory Malignancies Associated With Epstein-Barr Virus (EBV)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT05039580","title":"Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":36,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04476459","title":"Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":33,"lead_sponsor_name":"Huiqiang Huang","has_results":false},{"nct_id":"NCT07133776","title":"Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"The Affiliated Hospital of Xuzhou Medical University","has_results":false},{"nct_id":"NCT04796857","title":"Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Huiqiang Huang","has_results":false},{"nct_id":"NCT06789159","title":"A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT05677178","title":"Response Prediction in EBV-HLH Using Metabonomics Analysis","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT06075927","title":"Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":29,"lead_sponsor_name":"Peking University People's Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}